Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in ...

There will also be talks by Phil Howe of Venture Security about the emerging security risks facing businesses and Andy Tamkus of EVOTEC Fire & Security. Businesspeople will also have plenty of ...

(Reuters) - Europe's STOXX 600 opened lower on Friday, dragged by technology and healthcare stocks, keeping the index on ...

德国汉堡 - 专注于药物发现和开发的制药公司Evotec SE今天向美国证券交易委员会提交了一份临时公告，回应了最近的媒体猜测。这家在法兰克福证券交易所以EVO为股票代码上市的公司，对有关其业务运营的报道作出了澄清。 在公告中，Evotec的首席执行官Christian Wojczewski表示："我们经常评估潜在的战略机会以提升股东价值，并将继续这样做。"Wojczewski强调，虽然公司愿意探 ...

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

Read about Halozyme Therapeutics, Riverstone and more in the latest Market Talks covering the Health Care sector.

Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s ...

Warburg Research analyst Christian Ehmann maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion). Shares traded ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...